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Abstract
Background: Central nervous system tuberculosis (CNS-TB) may be fatal even with treatment. Neutrophils are the
key mediators of TB immunopathology, and raised CSF matrix metalloproteinase-9 (MMP-9) which correlates to
neutrophil count in CNS-TB is associated with neurological deficit and death. The mechanisms by which neutrophils
drive TB-associated CNS matrix destruction are not clearly defined.
Methods: Human brain biopsies with histologically proven CNS-TB were stained for neutrophils, neutrophil elastase,
and MMP-9. Neutrophil MMP-9 secretion and gene expression were analyzed using Luminex and real-time PCR. Type
IV collagen degradation was evaluated using confocal microscopy and quantitative fluorescent assays. Intracellular
signaling pathways were investigated by immunoblotting and chemical inhibitors.
Results: MMP-9-expressing neutrophils were present in tuberculous granulomas in CNS-TB and neutrophil-derived
MMP-9 secretion was upregulated by Mycobacterium tuberculosis (M.tb). Concurrent direct stimulation by M.tb and
activation via monocyte-dependent networks had an additive effect on neutrophil MMP-9 secretion. Destruction of
type IV collagen, a key component of the blood-brain barrier, was inhibited by neutralizing neutrophil MMP-9.
Monocyte-neutrophil networks driving MMP-9 secretion in TB were regulated by MAP-kinase and Akt-PI3 kinase
pathways and the transcription factor NF-kB. TNFα neutralization suppressed MMP-9 secretion to baseline while
dexamethasone did not.
Conclusions: Multiple signaling paths regulate neutrophil-derived MMP-9 secretion, which is increased in CNS-TB.
These paths may be better targets for host-directed therapies than steroids currently used in CNS-TB.
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Background
Despite treatment, central nervous system tuberculosis
(CNS-TB) often results in severe neurological deficit and
frequent death. Dexamethasone, a recommended ad-
junct to CNS-TB treatment, improves mortality but does
not affect long-term neurological outcome [1, 2]. This
has been attributed to innate host factors such as the
LTA4 genotype [3], underscoring the role of host-driven
immunopathology in this devastating infection. Newer
interventions for CNS-TB are urgently needed to im-
prove both morbidity and mortality, particularly in the
era of rising drug resistance. Host-directed therapies
may be an attractive therapeutic strategy [4].
Neutrophils are emerging mediators of TB pathology.
These early sentinels to Mycobacterium tuberculosis in-
fection play the key roles in TB inflammation [5, 6].
Raised neutrophils are present in CNS-TB in the setting
of both HIV-negative and HIV-associated immune re-
constitution inflammatory syndrome and increased
neutrophil-associated mediators such as S100A calcium-
binding protein correspond to the degree of inflamma-
tion [7–9]. However, the mechanisms by which
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neutrophils cause neuroinflammation in CNS-TB are
not defined.
The development of severe neurological deficits may
be caused by local CNS tissue destruction. Tissue dam-
age may be driven by the host immune cells recruited to
the CNS such as neutrophils and macrophages [10, 11],
following disruption to the blood-brain barrier (BBB).
These cells secrete matrix metalloproteinases (MMPs),
zinc-containing proteases which degrade extracellular
matrix fibrils crucial for the integrity of the BBB [12].
MMPs are inhibited by specific tissue inhibitors of me-
talloproteinases (TIMPs). We and others found in-
creased MMP expression in CNS-TB and raised MMP
concentrations were associated with neurological deficit
and death [7, 8, 13]. In addition, mediators including
TNFα which is the key in the defense against myco-
bacteria and whose blockade leads to reactivation of
TB [14, 15], drive MMP secretion from the host cells
including the neutrophils and epithelial cells and may
have a role in CNS-TB immunopathology [16, 17]. In-
vestigating mechanisms by which MMPs result in tis-
sue damage may be the key in understanding the
pathogenesis of CNS neuroinflammation caused by
agents such as M.tb.
We hypothesized that neutrophils drive matrix de-
struction in CNS-TB. As humans are the primary host
of M.tb, we examined the brain biopsies of patients with
proven CNS-TB and investigated our findings in a hu-
man cellular model. Neutrophils expressing MMP-9 are
present in CNS tuberculous granulomas, and M.tb infec-
tion increased neutrophil MMP-9 secretion and gene ex-
pression. Neutrophil-derived MMP-9 was functionally
active and caused type IV collagen destruction, which
was reversed by neutralizing MMP-9. We demonstrate
that mitogen activated protein-kinase (MAP-kinase) and
the phosphoinositide-3 (PI3) kinase-Akt pathways regu-
lated neutrophil MMP-9 secretion in monocyte-dependent
intercellular networks. Neutralizing TNFα suppressed neu-
trophil MMP-9 to baseline, while dexamethasone did not,
which may partly explain the limited benefit of steroids in
patients. Taken together, our findings suggest that host-
directed therapy targeting MMP-9 secretion may have a
potential to limit immunopathology in CNS-TB.
Methods
Reagents and antibodies
Dexamethasone was from Sigma. Helenalin and SC-514
were from Merck Biochemicals. SB203580, PD98059,
and LY294002 were from Enzo Life Sciences. Goat anti-
human TNFα was from PeproTech. Mouse anti-human
MMP-9, rabbit anti-M.tb, and goat anti-rabbit IgG Cy5
were from Abcam. Rabbit anti-human phospho-Akt,
total-Akt, phospho-p38, total-p38, phospho-ERK, total-
ERK, phospho-JNK, total-JNK, and goat anti-rabbit HRP
linked were from Cell Signaling Technology. Rabbit
anti-human neutrophil elastase was from Dako, and
mouse anti-human MMP-9 was from Millipore.
Recruitment of patients and controls
Immunohistochemistry
The paraffin blocks of five surgical samples from immuno-
competent patients with CNS M.tb infection were re-
trieved from the files of the Department of Histopathology
at Imperial College Healthcare Trust, London. All speci-
mens contained leptomeninges, cortex, and subcortical
white matter and showed typical necrotizing granulomas
and acid-fast bacilli identified with the Ziehl-Neelsen
stain. Sections of caecal appendix with acute inflammation
were used as positive control for MMP-9 immunoreactiv-
ity. To prove the specificity of primary antibodies directed
against MMP-9 and elastases, we used sections from the
frontal lobe of five post-mortem brain with only mild
aging-related changes. The appendix and brains were also
retrieved from the files of the Department of Histopath-
ology at Imperial College. Samples were annonymized for
the purpose of this study. The cases were investigated
using immunoperoxidase immunohistochemistry with
antibodies directed against MMP-9 (Abcam; 1: 200) and
neutrophil elastase (Dako, clone NP57; 1/100). Immunos-
tains with omission of the primary antibody were per-
formed as negative controls. Five-micron sections were
cut from each block, dewaxed in xylene, and rehydrated in
decreasing alcohols to distilled water. Endogenous perox-
idase activity was blocked in 0.3% hydrogen peroxide in
methanol for 30 min. For antigen retrieval, sections were
steamed for 20 min in 0.01 M citrate, pH 6.5, and then
gently cooled in water. In order to block nonspecific bind-
ing of the primary antibody, sections were incubated with
10% normal goat serum for 10 min (Vector Laboratories,
Burlingame, California). The primary antibodies were ap-
plied overnight at 4 °C. After incubation, they were
washed for three times in PBS for 10 min each. Staining
was visualized using the VECTASTAIN Elite ABC Kit
(Vector Laboratories) following the manufacturer instruc-
tions using 2 ng/ml 3,3′-diaminobenzidine and 0.0075%
hydrogen peroxide in PBS as chromogen.
M.tb culture
M.tb H37Rv was cultured in supplemented Middlebrook
7H9 medium (BD Biosciences). For infection experi-
ments, mycobacteria were used at mid-logarithmic
growth at an optical density of 0.60 (Biowave cell density
meter; WPA).
Cell culture and stimulation
The whole blood from healthy volunteers were drawn in
preservative-free heparin and mixed with equal volumes
of 3% dextran saline to remove erythrocytes. Neutrophils
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were isolated from the resulting cell suspension using
Ficoll-Paque density centrifugation and three rounds of
hypotonic lysis. Neutrophil purity was over 95% by
FACS and viability >99% by trypan blue assay. In some
experiments, neutrophils were pre-incubated with spe-
cific inhibitors/agents as indicated for 30 min unless
otherwise stated. In all experiments involving live M.tb
H37Rv, tissue culture medium was sterile filtered
through 0.2 μm Anopore membranes (Millipore) before
removing from the containment level 3 tuberculosis la-
boratory. All experiments were performed using 4 h in-
cubations unless otherwise stated.
Primary human blood monocytes were prepared from
donor leukocyte cones from healthy donors (National
Blood Transfusion Service, UK). After density gradient
centrifugation (Ficoll-Paque) followed by adhesion puri-
fication, monocyte purity was over 95% by FACS ana-
lysis. Monocytes were infected with M.tb at a
multiplicity of infection (MOI) of 1. After incubation at
37 °C for 24 h, conditioned medium was harvested and
was termed CoMTB. Media from uninfected monocytes
were termed CoMCont.
ELISAs for TIMP-1/2, MPO, and NGAL
TIMP-1 and -2 concentrations were measured using the
Duoset ELISA Development System (R&D Systems) and
detected a minimum of 31.2 pg/ml for both. Myeloperoxi-
dase (MPO) was measured using the human MPO Quanti-
kine ELISA Kit (R&D Systems) which had a minimum
detection limit of 0.1 ng/ml. Neutrophil gelatinase-
associated lipocalin (NGAL) was measured using the hu-
man NGAL ELISA Kit (BioPorto Diagnostics) which had
minimum detection limit of 1.6 pg/ml.
Luminex array
MMP-8 and -9 concentrations were analyzed by Fluoro-
kine MultiAnalyte Profiling Kit according to manufac-
turer’s protocol (R&D Systems) on the Luminex 200
platform (Bio-Rad). The minimum level of detection for
MMP-8 and -9 was 110 and 65 pg/ml, respectively.
DQ collagen degradation assay
Type IV collagen degradation was assessed using the
EnzChek ® Gelatinase/Collagenase Assay kit (Molecular
Probes). Samples were activated with 2 mM of 4-amino-
phenyl mercuric acetate (APMA) for 1 h at 37 °C. Eighty
microliters of reaction buffer or inhibitor (mouse anti-
human MMP-9) were added with 20 μL of DQ collagen
(Invitrogen) at a final concentration of 25 μg/ml. The ac-
tivated samples were subsequently added, and activity
was detected at specified times using a fluorometer
(FLUOstar Galaxy).
Immunoblotting
Pelleted neutrophils infected with M.tb or stimulated
with CoMTB were mixed with SDS lysis buffer. The
samples were run on the NuPAGE® 4-12% Bis-Tris gels
with SDS Running buffer (Invitrogen). Protein was
transferred onto a nitrocellulose membrane (GE Health-
care). Primary antibody was diluted in 5% BSA/0.1%
Tween and incubated overnight at 4 °C with agitation.
Secondary antibody was added diluted in blocking buf-
fer. Luminescence was demonstrated with ECL Substrate
Reagent (Amersham Science) according to manufac-
turer’s instructions and exposing the membrane to
Hyperfilm ECL. Densitometric analysis was performed
using ImageJ 1.43U (NIH, USA).
Real-time PCR
Total RNA was extracted from 2 × 106 neutrophils using
the RNeasy Mini Kit (Qiagen). Quantitative real-time RT-
PCR was performed using the One-Step RT-PCR Master
Mix (Qiagen) according to manufacturer’s instruction on
a Stratagene Mx3000P platform using 5–10 μg per sam-
ple. MMP-9 (forward primer 5′-AGGCGCTCATGTAC
CCTATGTAC-3′, reverse primer 5′-GCCGTGGCT
CAGGTTCA-3′, Probe 5′-FAM-CATCCGGCACCTCT
ATGGTCCTCG-TAMRA-3′) with glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) (Forward primer
5′-CGCTTCGCTCTCTGCTCCT-3′, reverse primer
5′-CGACCAAATCCGTTGACTCC-3′, probe 5′-HEX-
CGTCGCCAGCCGAGCCACAT-TAMRA-3′) was ana-
lyzed in parallel. To accurately determine the quantitative
change in RNA, standard curves were prepared from plas-
mids subjected to real-time PCR as above. MMP-9 data
were normalized to GAPDH detected in the same sample.
Immunofluorescence microscopy
Permanox chamber slides (Nunc Lab-Tek) were coated
with 25 μg/ml of DQ collagen for 30 min. The samples
were then fixed with 4% paraformaldehyde for 30 min
and permeabilized with 0.5% saponin for 10 min. The
cells were washed before blocking with 10% human AB
serum with 2.5% BSA and 0.05% saponin. Primary anti-
bodies were added overnight. Chamber slides were
washed prior to the addition of secondary antibodies.
The chambers were subsequently removed from the
slide, and saline was added. Images were captured using
Leica confocal microscope (Leica TCS SP5) and proc-
essed using Leica LAS AF Lite 2.6.0 (Leica Microsys-
tems, Germany) and ImageJ 1.43U (NIH, USA).
Flow cytometry
Cell viability was assessed by staining neutrophils with
annexin V and propidium iodide using Annexin V-
FITC Apoptosis Detection Kit (eBioscience, Affymetrix,
California, USA) and LIVE/DEAD Fixable Stain Kit
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(Invitrogen). Neutrophils were stimulated with 200 ng/ml
staurosporine to induce apoptosis, and this was used as a
positive control for all experiments. Annexin V was de-
tected on the FL-1 channel with propidium iodide and
LIVE/DEAD Fixable Dead Cell Stain Kit on FL-3. A total
of 50,000 events were gated and analyzed on BD FACSCa-
libur flow cytometer using CellQuest. Data was analyzed
using FlowJo 7.6.5 (Tree Star).
Statistical analyses
Data were analyzed using GraphPad Prism (version 5.04,
GraphPad Software). Data are expressed as mean ± s.d.
unless stated otherwise. All experiments are performed
in biological triplicates on at least two separate occa-
sions. Multiple intervention experiments are compared
with one-way ANOVA followed by Tukey’s post-test cor-
rection, while continuous variables between two sets of
data are assessed using two-tailed Mann-Whitney U test.
Spearman’s rank correlation tests are used for correl-
ation analyses. P values of less than 0.05 are taken as sta-
tistically significant.
Results
Neutrophils express MMP-9 in response to direct M.tb
infection or stimulation by M.tb-driven monocyte-dependent
networks and in patients with CNS-TB
First, we investigated MMP-9 secretion from primary
human neutrophils in TB. Neutrophil MMP-9 secretion
increased over 4 h in response to M.tb infection (Fig. 1a,
P < 0.0001). By 24 h, more than 80% of neutrophils were
non-viable after infection by flow cytometry staining of
annexin V and propidium iodide. Intercellular networks
are crucial in TB [18], so we evaluated the effect of cross
talk between neutrophils and monocytes [19] by using
conditioned media from monocytes infected by M.tb
(CoMTB). CoMTB stimulation caused significant upreg-
ulation of MMP-9 secretion by 3.5-fold compared to
CoMCont (Fig. 1b, P < 0.0001). CoMTB increased neutro-
phil MMP-9 gene expression 8.6-fold (Fig. 1c, P < 0.001).
As direct M.tb infection and intercellular network interac-
tions occur simultaneously in TB, we investigated the ef-
fect of concurrent M.tb and CoMTB stimulation of
neutrophils and demonstrated an additive effect on MMP-
9 secretion (Fig. 1d). We also analyzed the secretion of
NGAL which can restrict the growth ofM.tb [20]. Neutro-
phil MMP-9 secretion closely correlated with the secre-
tion of NGAL in response to both M.tb and CoMTB
stimulation (Fig. 1e; r = 0.9, P < 0.0001).
To determine whether neutrophils express MMP-9 at
the site of disease in patients with CNS-TB, we analyzed
specimens from patients who underwent diagnostic bi-
opsies. Polymorphonuclear neutrophils were observed
around the granuloma on H & E staining (Fig. 1f ). Neu-
trophil accumulation was confirmed by specific positive
staining for neutrophil elastase and MMP-9 (Fig. 1g, h).
MMP-9 was also seen in the blood vessel wall and peri-
vascular interstitium (Fig. 1j). The M.tb-infected brain
tissue with secondary antibody alone showed no immu-
noreactivity (Fig. 1k).
M.tb-infected neutrophils degrade basement membrane
matrix
Type IV collagen is the main extracellular matrix fibril in
the basement membrane of the BBB [21]. Therefore, we
assessed the functional activity of neutrophil MMP-9 on
this key structural protein. Confocal microscopy demon-
strated type IV collagen degradation at the neutrophil-
collagen interface in M.tb-infected neutrophils, but not
uninfected neutrophils (Fig. 2a). Increased collagenase ac-
tivity after M.tb infection was confirmed by a quantitative
fluorescence assay (Fig. 2b). Pre-treatment of M.tb-stimu-
lated neutrophil supernatants with neutralizing anti-
MMP-9 antibody caused a dose-dependent inhibition of
collagenase activity with a maximal effect at 10 μg/ml
(Fig. 2b, P < 0.01), demonstrating that this collagenolysis
was MMP-9 dependent.
Neutrophil MAP-kinase pathways regulate CoMTB-induced
MMP-9 secretion
Next, we investigated the neutrophil intracellular path-
ways regulating MMP-9 secretion. As the MAP-kinase
pathway regulates MMPs in other CNS cell types [22], we
evaluated components of the pathway following CoMTB
stimulation of neutrophils. Immunoblotting revealed
phosphorylation of p38, ERK, and JNK with correspond-
ing increase of phospho-kinase to total kinase ratio after
CoMTB stimulation (Fig. 3a–d). Using targeted inhibitors
against p38 and ERK [23], we demonstrated a 48% MMP-
9 inhibition with 10 μM of p38 inhibitor SB203580 (Fig. 3e,
P < 0.001) and a 15% inhibition with 10 μM of ERK inhibi-
tor PD98059 compared to neutrophil stimulation with
CoMTB alone (Fig. 3f, P < 0.05). With live virulent M.tb
stimulation, we demonstrated phosphorylation of the p38
and ERK components of the MAP kinase pathway
(Fig. 3g–i). However, in contrast to CoMTB stimulation,
pre-incubation of neutrophils with p38 inhibitor or ERK
inhibitors did not suppress MMP-9 secretion after M.tb
infection (Fig. 3j, k).
The Akt pathway is activated and regulates MMP-9 secre-
tion after CoMTB stimulation but not direct M.tb infection
The PI3 kinase-Akt pathway regulates bronchial epithe-
lial cell-derived MMPs in TB [24]. We had previously
shown that Akt was phosphorylated in the presence of
CoMTB [6] and therefore investigated if this path also
regulates neutrophil MMP-9 secretion. Pre-treating neu-
trophils with PI3 kinase inhibitor LY294002 showed a
dose-dependent suppression of MMP-9 of 1.6-fold with
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CoMTB stimulation (Fig. 4a, P < 0.01). Similarly with
M.tb, Akt was phosphorylated, indicating activation
(Fig. 4b). However, PI3kinase inhibitor LY294002 did not
inhibit neutrophil MMP-9 secretion with M.tb stimula-
tion (Fig. 4c).
Transcription factor NF-kB regulates neutrophil MMP-9
in TB
NF-kB is one of the crucial transcription factors driving
inflammation in TB [6]. We evaluated if NF-kB regu-
lated neutrophil MMP-9 secretion by using NF-kB p65
Fig. 1 Neutrophils secrete MMP-9 and are present in CNS-TB. a M.tb infection with MOI of 1 upregulates neutrophil MMP-9 secretion. b Neutro-
phils from healthy volunteers secrete MMP-9 in response to CoMTB. c Kinetics of Neutrophil MMP-9 gene expression after CoMTB stimulation. d
M.tb and CoMTB stimulation have an additive effect on neutrophil MMP-9 secretion. e NGAL and MMP-9 concentrations closely correlate despite
being located in different neutrophil granules. f–h Neutrophils expressing MMP-9 are present in CNS TB granulomas and present in vessel walls
and perivascular interstitial space. f H&E, scale bar 250 μm. g Elastase immunoperoxidase, scale bar 250 μm and h MMP-9 immunoperoxidase, ×20
magnification, scale bar 50 μm. Inset shows neutrophils within lesions (×40). Positive control on acute appendicitis with i elastase, scale bar 50 μm
and j MMP-9 on blood vessel wall and interstitium, scale bar 200 μm. k Negative control with omission of primary antibodies, scale bar represents
100 μm. Bars represent mean ± s.d and represent at least two independent experiments performed in triplicate. *P < 0.05; **P < 0.01;
***P < 0.001; ****P < 0.0001
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subunit inhibitor helenalin (IC50 10–50 μM) and IKK2
inhibitor SC-514 (IC50 3–12 μM). In the presence of
CoMTB stimulation, we demonstrated a dose-dependent
suppression of neutrophil MMP-9 to baseline with hele-
nalin (Fig. 5a, P < 0.001). Suppression of neutrophil
MMP-9 secretion was similarly achieved with SC-514
(Fig. 5b, P < 0.01). Pre-treating neutrophils with helena-
lin before M.tb infection also resulted in a decrease in
neutrophil MMP-9 secretion, which was maximal at a
dose of 100 μM (Fig. 5c, P < 0.001), but at higher con-
centrations, neutrophil viability declined markedly to
less than 70% by FACS. Therefore, NF-kB regulates neu-
trophil MMP-9 secretion for both direct infection and
intercellular networks.
Anti-TNFα suppresses neutrophil MMP-9 secretion, but
dexamethasone does not
Neutrophil MMPs are raised in CNS-TB [8], and anti-
TNFα antagonists have been used to treat severe para-
doxical reaction in CNS-TB with improvement to neuro-
logical outcome [25, 26]. We investigated the effect of
TNFα neutralizing antibodies on neutrophil MMP secre-
tion. Pre-incubating CoMTB with anti-TNFα prior to
stimulating human neutrophils resulted in suppression
of MMP-9 secretion and gene expression which was
maximal at a dose of 5 μg/ml (Fig. 6a, b; P < 0.01 and
P < 0.001, respectively). TIMP-1 secretion was un-
affected by anti-TNFα (Fig. 6c) while TIMP-2 secre-
tion was slightly suppressed in a dose-dependent
manner (Fig. 6d, P < 0.01). Dexamethasone is an
established adjunct treatment for patients with CNS-
TB that improves mortality but does not significantly
affecting neurological outcome [1], so we investigated
the effect of dexamethasone on neutrophil MMP se-
cretion. MMP-9 secretion was unaffected by dexa-
methasone at a dose of 5 μg/ml, similar to the dose
used in clinical trials (Fig. 6e). However, CoMTB-
driven neutrophil MMP-8 secretion was inhibited by
32% (Fig. 6f, P < 0.001). We also evaluated if TNFα
drove neutrophil MMP-9 secretion in M.tb infection,
but this was not altered.
Discussion
CNS-TB is a devastating infection driven by an excessive
host immune response to infection and results in neuro-
logical morbidity and death. Our findings reveal a mech-
anism by which neutrophils contribute to tissue
destruction in the brain, further supporting the role of
the granulocyte in CNS-TB pathogenesis [8, 9, 27]. We
have demonstrated that neutrophils within granulomas
express MMP-9 in the brain biopsies from patients with
proven CNS-TB, further highlighting the role of MMPs
in pathology of TB granulomas [28]. Neutrophils secrete
MMP-9 in response to both direct M.tb infection and
monocyte-dependent networks in CNS-TB. The com-
bination of the two stimuli has an additive effect to
MMP-9 secretion, which is partially driven by TNFα, as
demonstrated by a decrease in MMP-9 with the addition
of neutralizing anti-TNFα antibodies in CoMTB stimula-
tion. The secretion of MMP-9 from neutrophils results
in the destruction of type IV collagen, a major constitu-
ent of the basement membrane in the BBB, and this was
inhibited by neutralizing MMP-9. This observation may
explain why increased MMP-9 expression in CNS
Fig. 2 Collagen is degraded by neutrophils stimulated with M.tb in an MMP-9 dependent manner. a Confocal microscopy of Type IV DQ collagen
coated slides demonstrating collagen degradation in the presence of M.tb stimulation. DQ collagen fluorescence increases after degradation. b
Type IV collagenase activity is inhibited by MMP-9 neutralizing antibody. Bars represent mean ± s.d and represent two independent experiment
performed in triplicate. **P < 0.01
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Fig. 3 (See legend on next page.)
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diseases corresponds to BBB disruption and is associated
with neurological deficit and death [13, 29]. There are
several potential targets in the MMP-9 regulatory path-
way for host-directed therapy in CNS-TB, and of note,
both specific and broad-based MMP-inhibitors are cur-
rently being explored as adjunctive therapy in other
CNS-diseases such as autoimmune encephalomyelitis
and stroke [30, 31].
We explored potential intracellular switch points in
the regulation of neutrophil MMP-9 secretion and
showed that the MAP-kinase, Akt-PI3 kinase, and NF-kB
have the key roles. This is consistent with our findings
of MMP regulation in other CNS cells such as astrocytes
and microglial cells [32–34]. However, we observed di-
vergent effects with M.tb and CoMTB stimulation on
neutrophil intracellular signaling pathways. In the pres-
ence of virulent M.tb, neutrophil MMP-9 secretion was
not suppressed by targeted chemical inhibitors of
intracellular signaling paths upstream of transcription.
In contrast, CoMTB, which contains cytokines including
TNFα, results in neutophil MMP-9 secretion and this
secretion was decreased by blockade of the p38 and ERK
MAP kinases and PI3 kinase paths. This was in contrast
to previous findings that TNFα-induced neutrophil
MMP-9 secretion is independent of the p38 and ERK ki-
nases [16]. We postulate the differences caused by
CoMTB and M.tb may in part be due to M.tb triggering
cellular necrosis in neutrophils that we and others dem-
onstrated [35], leading to unregulated release of their
proteases, and consequently, pathway modulation did
not affect total MMP-9 release. This highlights the im-
portance of monocytes in mediating neutrophil secretion
of MMP-9 that drives matrix destruction in TB.
NF-kB inhibition decreased neutrophil MMP-9 secre-
tion in response to both direct infection and monocyte-
dependent networks. We have previously demonstrated
(See figure on previous page.)
Fig. 3 MAP-kinase pathways are activated in neutrophils in TB and regulate MMP-9 secretion. a Representative immunoblots of p-38, ERK, and
JNK MAP kinases in neutrophils stimulated with CoMTB. CoMTB increases phosphorylation of all pathways from 15 min. Densitometric analysis of
response to CoMCont and CoMTB stimulation of b phospho-p38 to total p38, c phospho-ERK to total ERK, and d phospho-JNK to total JNK.
e CoMTB-stimulated MMP-9 secretion is suppressed by p-38 inhibitor SB203580. f MMP-9 secretion with CoMTB is inhibited by ERK inhibitor
PD98059. g Representative immunoblots to detect p-38, ERK MAP kinases in neutrophils stimulated with M.tb. Densitometric analysis of response
to control (PBS) and M.tb infection of h phospho-p-38 to total p-38 and i phospho-JNK to total JNK. j Pre-incubation with p-38 inhibitor SB does
not suppress MMP-9 secretion in M.tb-infected neutrophils. k Pre-incubation with ERK inhibitor PD does not affect MMP-9 secretion by M.tb-stimu-
lated neutrophils. All chemical inhibitor experiments were performed by pre-incubating neutrophils for 30 min before stimulating for 4 h. Bars
represent mean ± s.d and are representative of at least two independent experiments performed in triplicate. *P < 0.05; **P < 0.01; ***P < 0.001
Fig. 4 The Akt pathway regulates neutrophil MMP-9 secretion in TB. a Pre-incubation with PI3-kinase inhibitor LY294002 suppresses MMP-9 secretion
with CoMTB. b Representative immunoblots to detect p-Akt in neutrophils infected with M.tb show increased phosphorylation with corresponding
densitometric analysis. c Pre-incubation with PI3-kinase inhibitor LY does not affect MMP-9 secretion after M.tb infection. Bars represent mean ± s.d and
are representative of at least two independent experiments performed in triplicate. *P < 0.05; **P < 0.01
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that NF-kB inhibition decreased neutrophil MMP-8 se-
cretion which drove type I collagen degradation [6], a fi-
bril which is important in lung TB but minimally
present in the central nervous system. We now demon-
strate that neutrophil MMP-9, which drives destruction
of type IV collagen present in the BBB, is suppressed by
NF-kB inhibition. Thalidomide inhibits NF-kB by sup-
pressing IkB kinase activity [36] and has been used to
treat paradoxical reaction in CNS-TB [37, 38], but its
considerable side effects such as teratogenicity and per-
ipheral neuropathy mean that its potential as use for a
host-directed therapy will be very limited.
Finally, we investigated the effects of anti-TNFα
and dexamethasone on neutrophil MMP-9 secretion
and found that anti-TNFα treatment significantly
inhibited neutrophil MMP-9 secretion, while dexa-
methasone partially inhibited MMP-8 but did not
affect MMP-9 secretion. The lack of response of neu-
trophil MMPs to dexamethasone was unexpected,
given our previous finding that dexamethasone de-
creased CSF MMP-9 in a cohort of Vietnamese pa-
tients with CNS-TB [8]. The cells other than
neutrophils such as the astrocytes, microglial, and
neuronal cells also secrete MMP-9 and may contrib-
ute to the total suppression of CSF MMP-9 causing
the effect that we previously observed. Glucocorti-
coids are established adjuncts to treatment of CNS-
TB and inhibit NF-kB activity through induction of
IkB synthesis, among other mechanisms, to decrease
inflammatory responses and decrease MMP-9 [39].
However, steroids have significant off-target effects
such as immunosuppression, steroid-induced diabetes
mellitus, and Cushing’s syndrome. Anti-TNFα inhibi-
tors are sometimes used to treat refractory paradox-
ical reactions in CNS-TB [25, 26] and may lead to
improved neurological outcome by decreasing MMP-
9 secretion.
Our study has limitations, including the use of
chemical inhibitors, which may have off-target effects,
to evaluate intracellular signaling pathways in neutro-
phils. Ideally, selective pathway inhibition using
siRNA would be more specific. However, this is tech-
nically challenging in primary neutrophils as they die
rapidly in vitro and hence, we and others have been
unable to proceed with this approach. Also, our find-
ings of TNFα in mediating neutrophil MMP secretion
have to be carefully interpreted in clinical care as
there is a potential optimal concentration for host
control of infection [18]. While excessive TNFα drives
paradoxical TB reactions, blocking TNFα can lead to
reactivation of latent TB [15, 40], so any therapeutic
intervention requires very careful evaluation.
Conclusions
In summary, we show MMP-9 is expressed by neutro-
phils during the host response in CNS-TB. Neutrophil
MMP-9 gene expression and secretion are driven by
Fig. 5 Neutrophil MMP-9 secretion is regulated by NF-kB. a Pre-
incubation with helenalin inhibits MMP-9 secretion after CoMTB
stimulation. b Pre-incubation with IKK2 inhibitor SC-514 inhibits
MMP-9 secretion with CoMTB stimulation. c Pre-incubation with
NF-kB inhibitor helenalin inhibits MMP-9 secretion after M.tb infection.
Bars represent mean ± s.d and are representative of at least two inde-
pendent experiments performed in triplicate. **P < 0.01; ***P < 0.001
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both direct effects of M.tb infection and monocyte-
dependent networks. Destruction of type IV collagen, a
major component of the BBB, is driven by neutrophil
MMP-9. The MAP-kinase and Akt-PI3 kinase pathways
regulate MMP-9 secretion through monocyte-dependent
networks but not after direct M.tb infection. Neutraliz-
ing TNFα significantly suppressed neutrophil MMP-9
secretion and gene expression. Host-directed therapies
that target MMPs and the key regulatory pathways
should be evaluated to improve neurological and mortal-
ity outcomes in CNS-TB.
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